[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607699":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":38,"collaborators":43,"id":54,"slug":10,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adrenal cohort",null,"Aged between 18 and 75 years; diagnosed with adrenal diseases, including primary aldosteronism, pheochromocytoma, Cushing's syndrome, congenital adrenal hyperplasia, adrenocortical carcinoma, etc.; in stable condition, capable of tolerating all examinations and follow-ups required by the study.",[13],"Other: Receive adrenal surgery, radiotherapy, and\u002For medication therapy based on diagnosis and subtype classification.",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Receive adrenal surgery, radiotherapy, and\u002For medication therapy based on diagnosis and subtype classification.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Yiran Jiang","CONTACT","0086-021-64370045","jyr11662@rjh.com.cn",[25],{"facility":26,"status":27,"city":28,"state":10,"zip":10,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Jiang yiran","RECRUITING","Shanghai","China",{"type":31,"coordinates":32},"Point",[33,34],121.45806,31.22222,{"lat":34,"lon":33},[37],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":42,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Wang Weiqing","Director of the Department of Endocrinology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","Ruijin Hospital",[44,47,49,51],{"name":45,"class":46},"Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","UNKNOWN",{"name":48,"class":6},"RenJi Hospital",{"name":50,"class":6},"Shanghai Zhongshan Hospital",{"name":52,"class":53},"Shanghai Public Health Clinical Center","OTHER_GOV","100607699",false,"NCT07191951","Shanghai Clinical Cohort - Adrenal Disease","Inclusion Criteria:\n\n* A signed and dated informed consent form\n* Commitment to abide by the study procedures and cooperate with the implementation of the entire study process\n* Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and\u002For medication therapy\n* Aged between 18 and 75 years\n\nExclusion Criteria:\n\n* Subjects meeting any of the following criteria will be excluded from this study:\n* Refuse to sign the informed consent form\n* Patients without adrenal diseases\n* Have specified diseases or conditions (physical or psychological, identified through physical examination) that warrant exclusion from the study","ALL","18 Years","75 Years",{"count":63,"type":64},600,"ESTIMATED","OBSERVATIONAL","As a vital organ responsible for producing life-sustaining hormones, the adrenal gland is associated with a wide range of diseases. These diseases affect multiple systems throughout the body and carry a high rate of mortality and disability. Current diagnosis and treatment face several challenges: significant variability in hormone testing results, inaccurate localization via imaging techniques, unclear molecular characteristics of adrenal tumors, and difficulty in determining prognosis through pathology. Therefore, establishing a clinical research cohort for adrenal diseases is essential. Such a cohort will enable in-depth exploration of disease mechanisms, identification of disease subtypes, optimization of diagnostic criteria, evaluation of treatment efficacy, advancement of personalized medicine, and formulation of prevention and treatment strategies.",[68],"Adrenal Disease","2025-11-14",{"date":71,"type":72},"2025-11-17","ACTUAL",{"date":74,"type":72},"2025-07-25",{"date":76,"type":64},"2025-12-31",{"name":5,"class":6},1]